Barron's senior managing editor Lauren R. Rublin and healthcare reporter Josh Nathan-Kazis speak with RBC analyst Luca Issi about gene therapy and other innovations in biotechnology - and the best biotech stocks to buy now. Plus, an update on Covid vaccines and treatments.

*RBC Policies, Disclaimers & Disclosures: https://www.rbccm.com/en/policies-disclaimers.page

Thu, Jun 24, 2021 · 12:00 PM Eastern Time (US & Canada) (GMT -4:00)
Lauren Rublin
Senior Managing Editor
Lauren R. Rublin is the senior managing editor at Barron's, overseeing Roundtables and Special Projects. She previously worked in book publishing, and at Fairchild Publications and Time Inc.
Josh Nathan-Kazis
Health-care Industry Reporter , Barron's
Josh Nathan-Kazis is a reporter at Barron's, covering the healthcare industry. He is a former staff writer at the Forward, where he investigated nonprofits, covered local and national politics, and wrote about the institutions of the American Jewish community.
Luca Issi
Analyst, RBC
Luca Issi joined RBC Capital Market in 2020, and is covering Biotech. Prior to RBC, he was an investor at Bain Capital Life Sciences, where he led private and public investments across biopharmaceutical, medical device, specialty pharma and tools & diagnostics. Prior to Bain, he worked in equity research at Cowen and Company, where he covered large cap pharmaceutical companies. He received his PhD in Biotechnology from Worcester Polytechnic Institute and graduated summa cum laude in Biotechnology from the University of Milan (MS) and the University of Varese (BS).